Unlocking Cardiovascular Benefits: Which Patients Profit Most from SGLT2 and GLP-1 Diabetes Medications?
2025-02-06
Medical News Today
Recent research sheds light on the effectiveness of newer type 2 diabetes medications, specifically SGLT2 and GLP-1 inhibitors, in reducing the risk of cardiovascular disease. These medications have shown promise in improving cardiovascular health, particularly for patients with high cardiovascular risk. By analyzing the benefits of these treatments, healthcare professionals can better identify which patients are most likely to profit from SGLT2 and GLP-1 therapies, ultimately leading to more personalized and effective treatment plans. Key factors such as cardiovascular risk reduction and diabetes management are crucial in determining the efficacy of these medications.
